Is Sanofi SA (ADR)’s Latest Move For Real? The Stock Was Sold By Option Traders Today

 Is Sanofi SA (ADR)'s Latest Move For Real? The Stock Was Sold By Option Traders Today

In today’s session Sanofi SA (ADR) (SNY) recorded an unusually high (1,606) contracts volume of put trades. Someone, most probably a professional was a very active buyer of the November, 2016 put, expecting serious SNY decrease. With 1,606 contracts traded and 3544 open interest for the Nov, 16 contract, it seems this is a quite bearish bet. The option with symbol: SNY161118P00037000 closed last at: $0.8 or 33.3% up. About 3.21M shares traded hands or 18.45% up from the average. Sanofi SA (ADR) (NYSE:SNY) has declined 6.27% since March 10, 2016 and is downtrending. It has underperformed by 13.79% the S&P500.

Analysts await Sanofi SA (ADR) (NYSE:SNY) to report earnings on November, 3. They expect $0.87 EPS, down 2.25% or $0.02 from last year’s $0.89 per share. SNY’s profit will be $2.22 billion for 10.72 P/E if the $0.87 EPS becomes a reality. After $0.74 actual EPS reported by Sanofi SA (ADR) for the previous quarter, Wall Street now forecasts 17.57% EPS growth.

Sanofi SA (ADR) (NYSE:SNY) Ratings Coverage

Out of 7 analysts covering Sanofi-aventis Sa (NYSE:SNY), 3 rate it a “Buy”, 0 “Sell”, while 4 “Hold”. This means 43% are positive. Sanofi-aventis Sa has been the topic of 9 analyst reports since October 15, 2015 according to StockzIntelligence Inc. Morgan Stanley upgraded the stock to “Overweight” rating in Thursday, October 15 report. The firm earned “Overweight” rating on Thursday, May 12 by Barclays Capital. The firm has “Mkt Perform” rating given on Monday, November 9 by Bernstein. The firm has “Buy” rating by Berenberg given on Thursday, September 8. BNP Paribas upgraded Sanofi SA (ADR) (NYSE:SNY) on Tuesday, September 13 to “Neutral” rating. The firm has “Hold” rating by HSBC given on Tuesday, May 3. The rating was downgraded by BNP Paribas to “Underperform” on Thursday, December 10. Piper Jaffray initiated Sanofi SA (ADR) (NYSE:SNY) on Friday, September 23 with “Neutral” rating.

According to Zacks Investment Research, “Sanofi-Aventis is a global pharmaceutical company that contributes to enhance life by providing medicines, vaccines, and integrated healthcare solutions adapted to local needs and means primarily in Europe and the United States. The company is engaged in the research, development, manufacture and marketing of healthcare products. Its strategy is built around three priorities to reach its goals and ensure sustainable growth. The priorities are: increasing innovation in Research and Development, adapting Group structures to future challenges and seizing external growth opportunities. Sanofi-Aventis specializes in six therapeutic areas: thrombosis, cardiovascular, metabolic disorders, oncology, central nervous system (CNS) and internal medicine. The Company offers vaccines in five areas: pediatric combination vaccines, influenza vaccines, adult and adolescent booster vaccines, meningitis vaccines, and travel and endemic vaccines. Sanofi-Aventis is headquartered in Paris, France.”

Sanofi, formerly Sanofi-Aventis, is a healthcare firm engaged in the research, development, manufacture and marketing of therapeutic solutions. The company has a market cap of $95.20 billion. The Firm operates through three divisions: Pharmaceuticals, Human Vaccines and Animal Health. It has a 21.33 P/E ratio. The Pharmaceuticals segment consists of research, development, production and marketing of medicines, including those originating from Genzyme Corporation.

SNY Company Profile

Sanofi, formerly Sanofi-Aventis, incorporated on May 11, 1994, is a healthcare firm engaged in the research, development, manufacture and marketing of therapeutic solutions. The Firm has three operating divisions: Pharmaceuticals, Human Vaccines (Vaccines) and Animal Health. The Pharmaceuticals segment consists of research, development, production and marketing of medicines, including those originating from its subsidiary, Genzyme Corporation. The Company’s pharmaceuticals portfolio consists of products and a range of prescription medicines, generic medicines and consumer health products. The Pharmaceuticals segment also includes associates with activities related to pharmaceuticals. The Vaccines segment is dedicated to vaccines, including research, development, production and marketing. The Vaccines segment includes the Sanofi Pasteur MSD joint venture. The Animal Health segment includes the research, development, production and marketing activities of Merial, which offers a range of medicines and vaccines for a range of animal species. The Company’s Animal Health segment includes its subsidiaries, Merial, Inc. and Merial S.A.S. It also operates in the Other segment, which includes the effects of retained commitments in respect of divested activities.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Tags: , ,

Related posts

Leave a Comment